Provided by Tiger Fintech (Singapore) Pte. Ltd.

COSCIENS Biopharma Inc

3.29
+0.18005.79%
Post-market: 3.290.00000.00%17:19 EDT
Volume:59.16K
Turnover:190.13K
Market Cap:10.28M
PE:-0.23
High:3.65
Open:2.90
Low:2.72
Close:3.11
Loading ...

Cosciens Biopharma to Start Phase 2a of Inflammation Drug Candidate

MT Newswires Live
·
13 Mar

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

GlobeNewswire
·
13 Mar

Press Release: Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day

Dow Jones
·
28 Feb

Cosciens Biopharma provides update, reiterates pipeline prioritization

TIPRANKS
·
23 Dec 2024

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

GlobeNewswire
·
23 Dec 2024

COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)

Simply Wall St.
·
15 Nov 2024

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

GlobeNewswire
·
12 Nov 2024

Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations

PR Newswire
·
06 Nov 2024

COSCIENS Biopharma Announces Change to Board of Directors

GlobeNewswire
·
08 Oct 2024

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

GlobeNewswire
·
02 Oct 2024

Cosciens Biopharma Shares Fall on ALS Treatment Research End, Cost Cutting

Dow Jones
·
23 Sep 2024

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

GlobeNewswire
·
23 Sep 2024